Killer T cells surround a cancer cell Source: Alex Ritter, Jennifer Lippincott Schwartz & Gillian Griffiths, NIH
With a series of high profile phase 3 cancer immunotherapy combination trials expected to readout throughout 2018, what can we expect given the promise they may offer?
While many people tend to assume that a doublet should produce more efficacy than monotherapy, this isn’t always the case and there’s also the risk of increased toxicities.
That said, are there any hints and learnings we can garner from preclinical and clinical research that might help us assess some of the underlying challenges inherent in these randomised controlled trials?
I say yes there are and here we take a look at a couple of important indicators that may help understand what to expect ahead of time.
To learn more from our conference commentary and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Sunset in Puerta del Sol, Madrid
This is the last of our conference previews for #ESMO17 – after this we move on to the emerging data coming out from Madrid.
Most of the attention is rightly focused on the big phase 3 trial readouts that are eagerly expected, but what about some of the hidden gems from smaller companies?
What new IO and immunotherapies are looking interesting this year?
We have five such highlights for readers to watch out for. Things should get quite interesting over the next week or so.
Subscribers can log-in above to read our latest insights or you can click here to gain access to BSB Premium Content.